Technology | March 03, 2011

FDA Clears PET Imaging Reconstruction Application

FDA Clears PET Imaging Reconstruction Application

March 3, 2011 – The U.S. Food and Drug Administration (FDA) has cleared a whole-body positron emission tomography (PET) application. Xpress.PET, by UltraSpect, enables reduced dose and acquisition time without compromising image quality.

The benefits of application, which is based on the company’s Wide-Beam Reconstruction (WBR) technology in whole body PET/CT scanning include:

• Reduced PET acquisition time to 15 minutes for a whole body Fludeoxyglucose (FDG) PET/CT scan

• Reduced injection dose, minimizing patient radiation exposure

• Improved image signal to noise ratio

• Enhanced patient throughput and department productivity

• Greater patient tolerance and comfort during scanning

“With new Xpress.PET users can shorten scan times or reduce FDG dose up to 40 percent--reducing a typical PET scan to 15 minutes for most patients instead of 24 minutes,” said Mack Burris, R.T., clinical product specialist for UltraSpect. “Alternatively, an FDG dose of a normal patient can be reduced to 10 mCi from 15 mCi. The initial product will be released for the GE Discovery LS PET/CT system and will be adapted to other PET/CT devices shortly, and will make the performance of older PET/CT scanners comparable to newer models.”

WBR products accurately compensate for the physical effects in data acquisition, such as resolution, attenuation and scatter, while controlling the noise level. Physicians have the same clinical information as typical PET/CT technology in shorter time periods or with lower injection dose, minimizing radiation exposure to patients and staff, while enhancing efficiency and patient throughput.

For more information: www.ultraspect.com

Related Content

Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
Feature | PET Imaging | November 07, 2018 | By Greg Freiherr
Positron emission tomography (PET) is getting ready to venture outside oncology, cardiology and mainstream neurology....
Podcast | PET Imaging | November 07, 2018
PET is getting ready to venture outside oncology, cardiology and mainstream neurology.
PET Imaging Offers New Possibilities in Chronic Liver Disease Management

Hepatic 18F-FDG, 18F-FAC, and 18F-DFA accumulation are affected in a mouse model of autoimmune hepatitis. (A) Histochemical and immunohistochemical analyses of liver sections from vehicle- and ConA-treated mice. Scale bars represent 50 microns. Transverse PET/CT images (B) and quantification (C) of vehicle- and ConA-treated mice injected with 18F-FDG, 18F-FAC, and 18FDFA. Livers are outlined in a white dotted line. Quantification represents radiotracer accumulation in the liver normalized to a background organ. Image courtesy of Salas J.R., Chen B.Y., Wong A., et al.

News | PET Imaging | October 24, 2018
While liver biopsies are powerful and reliable, they are also invasive, painful, limited and subject to complications....
Huntsman Cancer Institute Installs First Preclinical nanoScan 3T PET/MRI in U.S.
News | PET-MRI | October 10, 2018
The Center for Quantitative Cancer Imaging at Huntsman Cancer Institute (HCI) at the University of Utah in Salt Lake...
Technology and Radionucleotide Development Will Fuel Mobile Gamma Camera Adoption
News | Nuclear Imaging | September 27, 2018
Advancements in healthcare technology, particularly in the surgery category, have led to an increasing adoption of...
Bruker Introduces New High-Performance Preclinical PET/CT Si78 System
Technology | PET-CT | September 26, 2018
September 26, 2018 — Bruker recently announced the introduction of the new preclinical...
PET Imaging Agent Predicts Brain Tau Pathology, Alzheimer's Diagnosis
News | PET Imaging | September 05, 2018
Eli Lilly and Co. and Avid Radiopharmaceuticals Inc. announced a Phase 3 study of positron emission tomography (PET)...